


## Product Data Sheet

### Oseltamivir

<b>Cat. No.:</b>	A3688
<b>CAS No.:</b>	196618-13-0
<b>Formula:</b>	C <sub>16</sub> H <sub>28</sub> N <sub>2</sub> O <sub>4</sub>
<b>M.Wt:</b>	312.4
<b>Synonyms:</b>	GS 4104; GOP-A-Flu; GS 4104; Tamiflu-Free; Tamvir
<b>Target:</b>	Microbiology & Virology
<b>Pathway:</b>	NA
<b>Storage:</b>	Store at -20°C



### Solvent & Solubility

≥31.2 mg/mL in DMSO; ≥119.4 mg/mL in EtOH with gentle warming; ≥82 mg/mL in H<sub>2</sub>O with gentle warming

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	<b>Concentration</b>			
	<b>1 mM</b>	3.2010 mL	16.0051 mL	32.0102 mL
	<b>5 mM</b>	0.6402 mL	3.2010 mL	6.4020 mL
	<b>10 mM</b>	0.3201 mL	1.6005 mL	3.2010 mL

Please refer to the solubility information to select the appropriate solvent.

### Biological Activity

Shortsummary

inhibitor of influenza neuraminidase

IC<sub>50</sub> & Target

In Vitro

#### Cell Viability Assay

Cell Line:	MDA-MB-231 and MCF-7 cells
Preparation method:	This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for

		several months.
	Reacting conditions:	500, 600, 700 and 800 µg/mL; 24, 48 and 72 hrs
	Applications:	In MDA-MB-231 and MCF-7 cells as well as their long-term Tamoxifen-resistant clones, Oseltamivir treatment dose-dependently reduced the sialidase activity associated with EGF-stimulated live cells and the cell viability after 72 hrs of incubation. Combination of 1 µM Cisplatin, 5-FU, Paclitaxel, Gemcitabine or Tamoxifen with Oseltamivir (≥ 300 µg/ mL) significantly reduced cell viability at 24, 48 and 72 hrs when compared to the chemodrug alone.
In Vivo	<b>Animal experiment</b>	
	Animal models:	RAGxCy double mutant mice bearing heterotopic xenografts of MDA-MB-231 tumors
	Dosage form:	30 and 50 mg/kg; i.p.
	Applications:	Compared with the untreated cohorts, Oseltamivir treatment (30 mg/kg, q.d., i.p.) reduced tumor vascularization and growth rate, as well as significantly reduced tumor weight and spread to the lungs. At the dosage of 50 mg/kg, Oseltamivir completely ablated tumor vascularization, tumor growth and spread to the lungs, with significant long-term survival at day 180 postimplantation, tumor shrinking, and no relapses after 56 days off-drug.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

1.Florek NW, Campos LM, et al. "An updated influenza A(H3N2) vaccine generates limited antibodyresponses to previously encountered antigens in children." Vaccine. 2017 Dec 14;pii: S0264-410X(17)31777-2.PMID:29249543

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1]. Haxho F, Allison S, Alghamdi F, Brodhagen L, Kuta VE, Abdulkhalek S, Neufeld RJ, Szewczuk MR. Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma. Breast Cancer (Dove Med Press). 2014 Dec 9;6:191-203.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable

---

under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



## **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

